McKesson Missed Earnings but Bought What

McKesson missed earnings expectations. Blame it on branded drug prices and a dip in GLP-1 sales. Yet, specialty pharma and oncology networks are thriving. CEO Tyler talks profit growth and acquisitions. Analysts grill management on growth and biosimilars. Stock dipped post-earnings. Is this a buying opportunity or a red flag? Discover more in our report.

Devon Energy's big move. Shareholders just cleared crucial votes. Coterra merger's almost a done deal. What could this mean for the energy market? Disruption or dominance? The stakes are high. Keep your eyes on this one. What might change in the energy landscape?

Prudential just hit pause on Japan sales. Surprise move. What's next for its stock? Investors are on edge. The ripple effects could be huge. Are analysts adjusting their forecasts? Could this impact earnings or guidance? Stay tuned. The market's watching closely. How will this move reshape Prudential's financial outlook?